Please login to the form below

Not currently logged in
Email:
Password:

Actavis makes two additions to board of directors

Michael R Gallagher and Peter J McDonnell join

Actavis has elected Michael R Gallagher and Peter J McDonnell to its board of directors.

Both Gallagher and McDonnell are former members of the board of directors for Allergan, whom Actavis completed its acquisition of this week.

Brent Saunders, CEO and president and Actavis, commented: “The addition of Michael and Peter brings significant experience from Allergan to our board and I welcome their insights and expertise as we combine our two dynamic organisations.

“I want to thank the entire Allergan board for their stewardship to Allergan shareholders in building a strong and successful company.”

Gallagher was elected to the Allergan board in 1998 and served as its lead independent director and chair of the organisation and compensation committee. 

In 2004, he retired as CEO and director of Playtex products where he joined in 1995. Prior to this, he held a number of senior roles at companies including Procter & Gamble and Reckitt & Colman.

McDonnell was appointed to the Allergan board in 2013 and served on the corporate governance and compliance committee and the science and technology committee. 

He has served as the chief medical editor of Ophthalmology Times and his research interests include the causes and correction of refractive error, corneal wound healing and microbial keratitis. 

20th March 2015

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics